Shots:

• The (EXPLORER-LTE) cohort of the (MAVA-LTE) study evaluates mavacamten (5mg, qd) vs PBO in a ratio (1:1) in 251 patients with symptomatic obstructive HCM for 30wks. Additionally, 200 patients remained in the study for 48+ wks., & 67 patients had reached 84wks.
• The interim analysis showed 94% patients remained on mavacamten, improvement in LVOT gradients, NYHA class & NT-proBNP levels @48 & 84wks., 67.5% & 60.2% improved by ≥1 NYHA & 1 NYHA classes from baseline with 7.3% by 2 NYHA classes @48wks. the safety results were consistent with (EXPLORER-HCM) study with no new safety signals
• Additionally, 10 (4.3%) permanently discontinued due to TEAEs & 26 (11%) discontinuing temporarily for any reason and resuming treatment thereafter

Ref: Businesswire | Image: BMS